Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study

Mehmet Yıldız; Ali Muhtaroğlu; Berkan Acar; Özdem Kavraz Tomar; Ahmet Dülger

doi:10.70058/cjm.1840542

Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study

This article was retracted on February 5, 2026. https://dergipark.org.tr/en/pub/cjm/article/1882760

Abstract

Objective: This study aimed to compare haematological, biochemical, and serological parameters in haemodialysis (HD) patients with Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) in order to identify distinctive laboratory patterns with potential clinical relevance. Methods: This cross-sectional study included 77 patients undergoing HD at a tertiary centre: 45 with AKI and 32 with CKD. Demographic characteristics and a broad panel of laboratory parameters encompassing haematological indices, inflammatory markers, liver and cholestatic enzymes, electrolyte and mineral metabolism, iron parameters, and serological markers were analysed. Group comparisons were performed using appropriate statistical tests. Receiver Operating Characteristic (ROC) analyses were conducted for Helicobacter pylori (HP) IgA and IgG. Results: Patients with AKI were significantly older than those with CKD (p=0.001), while sex distribution was similar. Compared with CKD patients, the AKI group demonstrated a laboratory profile characterised by higher inflammatory and tissue injury markers, including white blood cell count, neutrophils, C-reactive protein, lactate dehydrogenase, and D-dimer (all p<0.05). In contrast, CKD patients exhibited higher levels of creatinine, parathyroid hormone, ferritin, iron indices, and alkaline phosphatase, consistent with chronic kidney disease–related metabolic alterations (all p<0.05). No significant differences were observed in HP IgA or IgG levels, and ROC analyses showed no discriminative value for distinguishing AKI from CKD. Conclusion: HD patients with AKI and CKD exhibit distinct multisystem laboratory patterns reflecting acute inflammatory activity versus chronic metabolic adaptation. Recognising these differences may improve contextual interpretation of laboratory findings and support more individualised clinical decision-making in the HD setting.

Keywords

Ethical Statement

This study was approved by the Giresun Training and Research Hospital Clinical Research Ethics Committee (Committee Name: Giresun Eğitim ve Araştırma Hastanesi Klinik Araştırmalar Etik Kurulu; Date: 04.12.2023; Decision No: 04.12.2023/27). All procedures were conducted in accordance with the ethical standards of the institutional research committee and with the principles of the Declaration of Helsinki (revised 2024).

References

1. Ferenbach DA, Bonventre JV. Acute kidney injury and chronic kidney disease: from the laboratory to the clinic. Nephrol Ther. 2016;12(Suppl 1):S41–8. doi:10.1016/j.nephro.2016.02.005.
2. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int. 2012;82(5):516–24. doi:10.1038/ki.2012.208.
3. Yeh TH, Tu KC, Wang HY, Chen JY. From acute to chronic: unraveling the pathophysiological mechanisms of the progression from acute kidney injury to acute kidney disease to chronic kidney disease. Int J Mol Sci. 2024;25(3):1755. doi:10.3390/ijms25031755.
4. Strauß C, Booke H, Forni L, Zarbock A. Biomarkers of acute kidney injury: from discovery to the future of clinical practice. J Clin Anesth. 2024;95:111458. doi:10.1016/j.jclinane.2024.111458.
5. Koh ES, Chung S. Recent update on acute kidney injury-to-chronic kidney disease transition. Yonsei Med J. 2024;65(5):247-56. doi:10.3349/ymj.2023.0306.
6. Ozmen S, Akin D, Ozmen CA. A review to differentiate acute kidney injury from chronic kidney disease. J Adv Med Med Res. 2016;18(9):1–7. doi:10.9734/BJMMR/2016/29879.
7. Lu Z, Ni W, Wu Y, Zhai B, Zhao Q, Zheng T, et al. Application of biomarkers in the diagnosis of kidney disease. Front Med (Lausanne). 2025;12:1560222. doi:10.3389/fmed.2025.1560222.
8. Coca SG. Acute kidney injury in elderly persons. Am J Kidney Dis. 2010;56(1):122–31. doi:10.1053/j.ajkd.2009.12.034.

9. Yokota LG, Sampaio BM, Rocha EP, Balbi AL, Prado IRS, Ponce D. Acute kidney injury in elderly patients: narrative review on incidence, risk factors, and mortality. Int J Nephrol Renovasc Dis. 2018;11:217–24. doi:10.2147/IJNRD.S170203.
10. Heidari B. C-reactive protein and other markers of inflammation in hemodialysis patients. Caspian J Intern Med. 2013;4(1):611–6.
11. Beberashvili I, Omar MA, Nizri E, Stav K, Efrati S. Combined use of CRP with neutrophil-to-lymphocyte ratio in differentiating between infectious and noninfectious inflammation in hemodialysis patients. Sci Rep. 2023;13(1):5463. doi:10.1038/s41598-023-32270-8.
12. Ni Y, Wu W, Zhou H, Li M, Zhu X, Niu H, et al. Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients. BMC Nephrol. 2024;25(1):313. doi:10.1186/s12882-024-03751-3.
13. de Mutsert R, Grootendorst DC, Indemans F, Boeschoten EW, Krediet RT, Dekker FW, et al. Association between serum albumin and mortality in dialysis patients is partly explained by inflammation, and not by malnutrition. J Ren Nutr. 2009;19(2):127–35. doi:10.1053/j.jrn.2008.08.003.
14. Evenepoel P, Bover J, Ureña Torres P. Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int. 2016;90(6):1184–90. doi:10.1016/j.kint.2016.06.041.
15. Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int. 2017;21(Suppl 1):S21-7. doi:10.1111/ hdi.12556.
16. Tao M, Zheng D, Liang X, He Q, Zhang W. Diagnostic value of procalcitonin for bacterial infections in patients undergoing hemodialysis: a systematic review and meta-analysis. Ren Fail. 2022;44(1):81–93. doi:10.1080/0886022X.2021.2021236.
17. Lorton F, Veinberg F, Ielsch D, Deschênes G, Bensman A, Ulinski T. Procalcitonin serum levels in children undergoing chronic haemodialysis. Pediatr Nephrol. 2007;22(3):430–5. doi:10.1007/s00467-006-0304-2.
18. Takahashi N, Mori I, Asano M, Yamauchi M, Takuno H, Sato F, et al. Hemodialysis patients have lower prevalence of Helicobacter pylori infection: a case–control study. Ren Replace Ther. 2025;11:37. doi:10.1186/s41100-025-00638-3.

Details

Primary Language

English

Subjects

Internal Diseases

Journal Section

Research Article

Authors

Mehmet Yıldız ^*
0000-0003-0706-0906
Türkiye

Ali Muhtaroğlu
0000-0001-5412-2175
Türkiye

Berkan Acar
0000-0001-9798-295X
Türkiye

Özdem Kavraz Tomar
0000-0003-4697-2799
Türkiye

Ahmet Dülger
0000-0002-9328-5185
Türkiye

Early Pub Date

January 23, 2026

Publication Date

January 23, 2026

Submission Date

December 11, 2025

Acceptance Date

January 22, 2026

Published in Issue

Year 2026 Volume: 3 Number: 1

DOI

https://doi.org/10.70058/cjm.1840542

IZ

https://izlik.org/JA35TL78PX

Cite

RIS / Bibtex

APA

Yıldız, M., Muhtaroğlu, A., Acar, B., Tomar, Ö. K., & Dülger, A. (2026). Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study. Cerasus Journal of Medicine, 3(1), 18-27. https://doi.org/10.70058/cjm.1840542

AMA

1.Yıldız M, Muhtaroğlu A, Acar B, Tomar ÖK, Dülger A. Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study. Cerasus J Med. 2026;3(1):18-27. doi:10.70058/cjm.1840542

Chicago

Yıldız, Mehmet, Ali Muhtaroğlu, Berkan Acar, Özdem Kavraz Tomar, and Ahmet Dülger. 2026. “Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients With Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study”. Cerasus Journal of Medicine 3 (1): 18-27. https://doi.org/10.70058/cjm.1840542.

EndNote

Yıldız M, Muhtaroğlu A, Acar B, Tomar ÖK, Dülger A (January 1, 2026) Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study. Cerasus Journal of Medicine 3 1 18–27.

IEEE

[1]M. Yıldız, A. Muhtaroğlu, B. Acar, Ö. K. Tomar, and A. Dülger, “Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study”, Cerasus J Med, vol. 3, no. 1, pp. 18–27, Jan. 2026, doi: 10.70058/cjm.1840542.

ISNAD

Yıldız, Mehmet - Muhtaroğlu, Ali - Acar, Berkan - Tomar, Özdem Kavraz - Dülger, Ahmet. “Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients With Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study”. Cerasus Journal of Medicine 3/1 (January 1, 2026): 18-27. https://doi.org/10.70058/cjm.1840542.

JAMA

1.Yıldız M, Muhtaroğlu A, Acar B, Tomar ÖK, Dülger A. Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study. Cerasus J Med. 2026;3:18–27.

MLA

Yıldız, Mehmet, et al. “Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients With Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study”. Cerasus Journal of Medicine, vol. 3, no. 1, Jan. 2026, pp. 18-27, doi:10.70058/cjm.1840542.

Vancouver

1.Mehmet Yıldız, Ali Muhtaroğlu, Berkan Acar, Özdem Kavraz Tomar, Ahmet Dülger. Haematological, Biochemical, and Serological Differences Between Haemodialysis Patients with Acute Kidney Injury and Chronic Kidney Disease: A Cross-Sectional Comparative Study. Cerasus J Med. 2026 Jan. 1;3(1):18-27. doi:10.70058/cjm.1840542